T2	Premise 1336 1399	HRQOL and symptom relief were equivalent in the treatment arms.
T3	Premise 1400 1532	No significant difference in survival among arms A, B, and C was found, with median survival 8.2, 7.0, and 6.8 months, respectively.
T4	Claim 1533 1718	Our data indicate that protracted palliative TRT renders no improvement in symptom relief, HRQOL, or survival when compared with short-term hypofractionated treatment in advanced NSCLC.
R1	Support Arg1:T2 Arg2:T4	
R2	Support Arg1:T3 Arg2:T4	
